Allergan plc, AGN is in the exchange NYSE and its industry is Drugs – Generic in the sector of Healthcare. Based in USA, Allergan plc, AGN has a market cap of 72255.41. Since its IPO date on the 2/17/1993, Allergan plc, AGN performance year to date is -38.36%. Today Allergan plc, AGN has gained -0.38%, with a current price of 191.9.
Ownership of the company is 0.10% for insider ownership while institutional ownership is 88.40%. The management of the company have seen the company have a payout ratio of 0.00%. Return of assets are at 10.30%, with return on investment at -1.30%.
In terms of debt levels and profit levels, Allergan plc, AGN is seeing a long-term debt/equity of 0.37. While Total debt/equity is 0.39. With a profit margin of 94.40%, this is combined with a gross margin of 83.30%, and operating margin of -9.80%. Allergan plc ability to meet debt levels, with a current ratio of 4, while the quick ratio is 3.9.
For the last year Allergan plc, AGN has seen a EPS growth of 23.00%. A performance for the year of -38.63%. The 52-week high is -40.53%, and the 52-week low is 4.01%. The average volume for Allergan plc, AGN is 501072.
With a target price of 270.67, can Allergan plc, AGN reach this target? Looking at the value indicators of Allergan plc, AGN. Allergan plc has a P/E of *TBA and a forward P/E of 12. Perhaps the more useful indicator than P/E, is PEG which has a value of *TBA. Allergan plc also has a P/S and a P/B of 4.85 and 0.89 respectively. For P/cash, Allergan plc has a value of 2.64, while it is 30.52 for P/free cash flow.
At the current price of 191.9, Allergan plc has a dividend yield of 1.45%. We see a return on equity of 18.70%.
Looking more long-term Allergan plc, is projected to get an EPS growth for the next five years of 12.50%. In the short-term an EPS growth of 20.04% in the next year is forecasted. This is after a EPS growth of 23.00% for this year and for the last five years a -50.40% growth has been seen.